Financials
Financial year 2025
FOR PLUS PHARMA from Erquelinnes, company number BE0743663465, closed financial year 2025 with a result of € 82,647 after tax. For that financial year FOR PLUS PHARMA recorded a gross margin of € 98,379 and equity of € 99,809. Compared with financial year 2024, the result moved from € 1,200 to € 82,647. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on September 22, 2026.
€ 99,809
▲ € 82,647 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 82,647
▲ € 81,447 vs 2024
Profit after tax over the fiscal year.
€ 1,649
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 94,809.
People and assets in 2025
€ 28,163
▲ € 21,609 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 81,863
▲ 270% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 24,204
▼ 69% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -309 | € -31,712 | € 19,543 | € 98,379 | ▲ € 78,836 |
| Profit after taxes | € -7,158 | € -49,251 | € 1,200 | € 82,647 | ▲ € 81,447 |
| Equity | € 65,213 | € 15,962 | € 17,162 | € 99,809 | ▲ € 82,647 |
| Total debts | € 192,484 | € 236,979 | € 230,713 | € 285,642 | ▲ 24% |
| Cash | - | - | - | € 1,649 | |
| Retained profit | € 60,213 | € 10,962 | € 12,162 | € 94,809 | ▲ € 82,647 |
| Balance sheet total | € 257,697 | € 252,941 | € 247,875 | € 385,451 | ▲ 56% |
Key figures of FOR PLUS PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to FOR PLUS PHARMA?
What happened at FOR PLUS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 82,647 (▲ € 81,447 vs 2024). filed late Source: NBB ↗
- STEPHANE CAMBRAYE became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 7,158 loss in 2022 to € 82,647 profit in 2025.
Paid € 7,586 in corporate taxes since 2022.
Best year ever: 2025, with € 82,647 profit.
Management
Behind FOR PLUS PHARMA is STEPHANE CAMBRAYE. It owns 13% of LOCAL INVEST GROUP itself.
Directors
According to the 2025 annual accounts
since 2020
Establishments
Establishment units
Physical locations of this company
Espace Européen d'Entreprises 17 box B
6560 Erquelinnes
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0743.663.465
- VAT number
- BE 0743.663.465
- Registered office
- Espace Européen d'Entreprises 17 bus B, 6560 Erquelinnes
- Names & denominations
- FOR PLUS PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 14 February 2020
- Peppol
- Active · Active since 19 Feb 2026
- Activities · NACE
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren
Overige niet-gespecialiseerde detailhandel
Detailhandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen
Detailhandel via postorderbedrijven of via internet